Development and application of new radiopharmaceuticals in oncology and neuropsychiatry

New radioligands (radiopharmaceuticals as biomarkers) are being thought and developed from the bench to the clinical applications, following the pharmaceutical and radioprotection regulations to search for continuing improvement of diagnosis and therapy in oncology. In addition the group is seeking new avenues into the search and development of new molecules (mainly receptor based) to help with basic and clinical research in neuropsychiatry.